A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder

Takuya Masui, Ryota Hashimoto, Ichiro Kusumi, Katsuji Suzuki, Teruaki Tanaka, Shin Nakagawa, Tatsuyo Suzuki, Nakao Iwata, Norio Ozaki, Tadafumi Kato, Masatoshi Takeda, Hiroshi Kunugi, Tsukasa Koyama

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Lithium is one of the most commonly used drugs for the treatment of bipolar disorder. To prescribe lithium appropriately to patients, predictors of response to this drug were explored, and several genetic markers are considered to be good candidates. We previously reported a significant association between genetic variations in the breakpoint cluster region (BCR) gene and bipolar disorder. In this study, we examined a possible relationship between response to maintenance treatment of lithium and Asn796Ser single-nucleotide polymorphism in the BCR gene. Genotyping was performed in 161 bipolar patients who had been taking lithium for at least 1 year, and they were classified into responders for lithium mono-therapy and non-responders. We found that the allele frequency of Ser796 was significantly higher in non-responders than in responders. Further investigation is warranted to confirm our findings.

Original languageEnglish
Pages (from-to)204-208
Number of pages5
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume32
Issue number1
DOIs
Publication statusPublished - 01-01-2008

Fingerprint

Multigene Family
Bipolar Disorder
Lithium
Genetic Markers
Gene Frequency
Pharmaceutical Preparations
Single Nucleotide Polymorphism
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biological Psychiatry
  • Pharmacology

Cite this

Masui, Takuya ; Hashimoto, Ryota ; Kusumi, Ichiro ; Suzuki, Katsuji ; Tanaka, Teruaki ; Nakagawa, Shin ; Suzuki, Tatsuyo ; Iwata, Nakao ; Ozaki, Norio ; Kato, Tadafumi ; Takeda, Masatoshi ; Kunugi, Hiroshi ; Koyama, Tsukasa. / A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008 ; Vol. 32, No. 1. pp. 204-208.
@article{92d83579fb444acea9662ec8ee87b55c,
title = "A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder",
abstract = "Lithium is one of the most commonly used drugs for the treatment of bipolar disorder. To prescribe lithium appropriately to patients, predictors of response to this drug were explored, and several genetic markers are considered to be good candidates. We previously reported a significant association between genetic variations in the breakpoint cluster region (BCR) gene and bipolar disorder. In this study, we examined a possible relationship between response to maintenance treatment of lithium and Asn796Ser single-nucleotide polymorphism in the BCR gene. Genotyping was performed in 161 bipolar patients who had been taking lithium for at least 1 year, and they were classified into responders for lithium mono-therapy and non-responders. We found that the allele frequency of Ser796 was significantly higher in non-responders than in responders. Further investigation is warranted to confirm our findings.",
author = "Takuya Masui and Ryota Hashimoto and Ichiro Kusumi and Katsuji Suzuki and Teruaki Tanaka and Shin Nakagawa and Tatsuyo Suzuki and Nakao Iwata and Norio Ozaki and Tadafumi Kato and Masatoshi Takeda and Hiroshi Kunugi and Tsukasa Koyama",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/j.pnpbp.2007.08.010",
language = "English",
volume = "32",
pages = "204--208",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "1",

}

Masui, T, Hashimoto, R, Kusumi, I, Suzuki, K, Tanaka, T, Nakagawa, S, Suzuki, T, Iwata, N, Ozaki, N, Kato, T, Takeda, M, Kunugi, H & Koyama, T 2008, 'A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 1, pp. 204-208. https://doi.org/10.1016/j.pnpbp.2007.08.010

A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder. / Masui, Takuya; Hashimoto, Ryota; Kusumi, Ichiro; Suzuki, Katsuji; Tanaka, Teruaki; Nakagawa, Shin; Suzuki, Tatsuyo; Iwata, Nakao; Ozaki, Norio; Kato, Tadafumi; Takeda, Masatoshi; Kunugi, Hiroshi; Koyama, Tsukasa.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, No. 1, 01.01.2008, p. 204-208.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder

AU - Masui, Takuya

AU - Hashimoto, Ryota

AU - Kusumi, Ichiro

AU - Suzuki, Katsuji

AU - Tanaka, Teruaki

AU - Nakagawa, Shin

AU - Suzuki, Tatsuyo

AU - Iwata, Nakao

AU - Ozaki, Norio

AU - Kato, Tadafumi

AU - Takeda, Masatoshi

AU - Kunugi, Hiroshi

AU - Koyama, Tsukasa

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Lithium is one of the most commonly used drugs for the treatment of bipolar disorder. To prescribe lithium appropriately to patients, predictors of response to this drug were explored, and several genetic markers are considered to be good candidates. We previously reported a significant association between genetic variations in the breakpoint cluster region (BCR) gene and bipolar disorder. In this study, we examined a possible relationship between response to maintenance treatment of lithium and Asn796Ser single-nucleotide polymorphism in the BCR gene. Genotyping was performed in 161 bipolar patients who had been taking lithium for at least 1 year, and they were classified into responders for lithium mono-therapy and non-responders. We found that the allele frequency of Ser796 was significantly higher in non-responders than in responders. Further investigation is warranted to confirm our findings.

AB - Lithium is one of the most commonly used drugs for the treatment of bipolar disorder. To prescribe lithium appropriately to patients, predictors of response to this drug were explored, and several genetic markers are considered to be good candidates. We previously reported a significant association between genetic variations in the breakpoint cluster region (BCR) gene and bipolar disorder. In this study, we examined a possible relationship between response to maintenance treatment of lithium and Asn796Ser single-nucleotide polymorphism in the BCR gene. Genotyping was performed in 161 bipolar patients who had been taking lithium for at least 1 year, and they were classified into responders for lithium mono-therapy and non-responders. We found that the allele frequency of Ser796 was significantly higher in non-responders than in responders. Further investigation is warranted to confirm our findings.

UR - http://www.scopus.com/inward/record.url?scp=38349048705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349048705&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2007.08.010

DO - 10.1016/j.pnpbp.2007.08.010

M3 - Article

C2 - 17822820

AN - SCOPUS:38349048705

VL - 32

SP - 204

EP - 208

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -